Jeantet advises Famar on the sale of five manufacturing sites to Delpharm
Paris, 26 Novembre 2019. Jeantet advised the pharmaceutical subcontractor Famar on the sale of five of its twelve manufacturing sites to its competitor and one of Europe’s leading pharmaceutical subcontractors, the French group Delpharm.
Through this transaction, Famar sells to Delpharm the activities of its three plants located in France, Orléans, l’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loir) and the shares of the entities operating the Bladel, Netherlands and Pointe-Claire, Quebec sites. These production sites represent a turnover of 250 million euros and a total workforce of 1,300 employees.
The Jeantet team was made up of Thierry Brun, Marianne Chevallier, Maxime Brotz and Maria Plakci for the M&A matters, Florent Prunet (Competition), Jean-Guillaume Follorou and Gabriel Di Chiara (Tax), Laetitia Ternisien (Labour) and Arnaud Colin (Real Estate).
Famar was also advised by August & Debouzy (Laurent Cotret and, Armelle Loste, M&A) on restructuring aspects, as well as by the investment bank Lazard (François Guichot-Pérère, Frédérik Rothenburger and Louis Ghesquière) on financial aspects.
Delpharm was advised by STC Partners (Delphine Barianiet Marie Gabiano (M&A), Pierre Bouley (Tax) and Angèle Vibert (Competition) for the legal aspects and Ekapartners (Eric Toulemonde and Marc-Aurèle Taverna) for the financial aspects.